IOA-244 is under clinical development by IOnctura and currently in Phase I for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase I drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IOA-244’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IOA-244 is under development for the treatment of solid tumors including advanced or metastatic melanoma, mesothelioma, ocular melanoma, uveal melanoma, follicular lymphoma, peripheral t-Cell lymphomas (PTCL), angioimmunoblastic t-Cell lymphoma (AITL)/immunoblastic lymphadenopathy, anaplastic large cell lymphoma (ALCL), natural killer cell lymphomas, non-small cell lung cancer, chronic idiopathic myelofibrosis (primary myelofibrosis), post-essential thrombocythemia myelofibrosis (Post-ET MF), post-polycythemia vera myelofibrosis (PPV-MF) and Non-Hodgkin Lymphoma. It acts by targeting phosphoinositide 3-kinase delta (PI3K delta). It was also under development for the treatment of fibrotic indications. It is administered through oral route.
iOnctura is a biopharmaceutical company developing precision drugs targeting the tumor-stroma-immune interface for cancer indications and fibrosis. iOnctura is headquartered in Geneva, Switzerland.
For a complete picture of IOA-244’s drug-specific PTSR and LoA scores, buy the report here.